Astellas Pharma GmbH
- A02 - Agentes para el tratamiento de alteraciones causadas por ácidos
- PHOSPHALUGEL oral suspension 2.476 g/15 ml
- B03 - Preparados antianémicos
- EVRENZO film-coated tablet 100 mg
- EVRENZO film-coated tablet 150 mg
- EVRENZO film-coated tablet 20 mg
- EVRENZO film-coated tablet 50 mg
- EVRENZO film-coated tablet 70 mg
- G04 - Urológicos
- BETMIGA prolonged-release tablet 50 mg
- OMNIC OCAS prolonged-release tablet 0.4 mg
- TAMSU-ASTELLAS prolonged-release capsule, hard 0.4 mg
- VESIKUR film-coated tablet 10 mg
- VESIKUR film-coated tablet 5 mg
- VESIKUR oral suspension 1 mg/ml
- J02 - Antimicóticos de uso sistémico
- MYCAMINE powder for solution for infusion 100 mg
- MYCAMINE powder for solution for infusion 50 mg
- L01 - Antineoplásicos
- PADCEV powder for solution for infusion 20 mg
- PADCEV powder for solution for infusion 30 mg
- XOSPATA film-coated tablet 40 mg
- L02 - Terapia endocrina
- XTANDI film-coated tablet 40 mg
- L04 - Inmunosupresores
- ADVAGRAF prolonged-release capsule, hard 0.5 mg
- ADVAGRAF prolonged-release capsule, hard 1 mg
- ADVAGRAF prolonged-release capsule, hard 3 mg
- ADVAGRAF prolonged-release capsule, hard 5 mg
- MODIGRAF granules for oral suspension 0.2 mg
- MODIGRAF granules for oral suspension 1 mg
- PROGRAF capsule, hard 0.5 mg
- PROGRAF capsule, hard 1 mg
- PROGRAF capsule, hard 5 mg
- PROGRAF concentrate for solution for infusion 5 mg/1 ml